Abstract
New oral anticoagulants (NOACs) including direct thrombin inhibitors (DTIs) and Xa inhibitors offer major advantages over vitamin K antagonists. Although officially these agents do not require monitoring, bleeding and ischemic events occur raising concerns for over or under inhibition during NOAC
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
